Bionano Genomics Inc Dossier
Qualitative Analysis
Business overview
Bionano Genomics, Inc. is a life sciences instrumentation company operating in the genome analysis space. The company is primarily known for its proprietary Saphyr and Stratys systems, which utilize Optical Genome Mapping (OGM) technology to detect structural variations (SVs) in DNA. These systems, along with the VIA software and Ionic Purification systems, enable researchers and clinicians to identify large-scale genomic rearrangements that are often missed by traditional next-generation sequencing (NGS) or cytogenetic methods like karyotyping and fluorescence in situ hybridization (FISH). Bionano operates globally, with its primary revenue streams derived from the sale of instruments, consumables, and software services across the Americas, EMEA, and Asia-Pacific regions.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A deliberate commercial pivot initiated in late 2024 to redirect focus away from aggressive instrument placement and instead maximize utilization of consumables (flow cells) and software among committed, routine users.
Expected impact: Aims to drive sustainable, high-margin recurring revenue and improve gross margins, which reached 49% in Q1 2026.
Systematic reduction of operating expenses through organizational restructuring, headcount reductions, and narrowing of product development focus to extend cash runway.
Expected impact: Significantly reduced GAAP operating expenses (down 55% in FY2025 to $46.5 million) to align the cost structure with current revenue levels.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire Purigen's proprietary isotachophoresis (ITP) technology for ultra-pure nucleic acid extraction and purification, complementing Bionano's optical genome mapping workflow.
Financial impact: Contributes to product and consumable revenue streams, though offset by overall cost-saving measures.
To acquire the platform-agnostic NxClinical software for genomic data analysis, visualization, and reporting, transitioning Bionano into a comprehensive data solutions provider.
Financial impact: Drives software and recurring service revenues, though software revenue experienced a 40% YoY decline in Q1 2026 due to a large prior-year transaction.
Strategic Partnerships
Securing Category I CPT codes and favorable payment determinations (such as the 47% increase for hematologic malignancies) is critical to establishing OGM as a standard-of-care cytogenetic assay.
Terms: Non-monetary; regulatory reimbursement determinations.